330 related articles for article (PubMed ID: 10690542)
1. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
Lah TT; Cercek M; Blejec A; Kos J; Gorodetsky E; Somers R; Daskal I
Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542
[TBL] [Abstract][Full Text] [Related]
2. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
Levicar N; Kos J; Blejec A; Golouh R; Vrhovec I; Frkovic-Grazio S; Lah TT
Cancer Detect Prev; 2002; 26(1):42-9. PubMed ID: 12088202
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of cathepsins B and L in primary human breast cancer.
Foekens JA; Kos J; Peters HA; Krasovec M; Look MP; Cimerman N; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
J Clin Oncol; 1998 Mar; 16(3):1013-21. PubMed ID: 9508185
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.
Thomssen C; Schmitt M; Goretzki L; Oppelt P; Pache L; Dettmar P; Jänicke F; Graeff H
Clin Cancer Res; 1995 Jul; 1(7):741-6. PubMed ID: 9816040
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
Harbeck N; Alt U; Berger U; Kates R; Krüger A; Thomssen C; Jänicke F; Graeff H; Schmitt M
Int J Biol Markers; 2000; 15(1):79-83. PubMed ID: 10763146
[TBL] [Abstract][Full Text] [Related]
6. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis.
Lah TT; Kalman E; Najjar D; Gorodetsky E; Brennan P; Somers R; Daskal I
Hum Pathol; 2000 Feb; 31(2):149-60. PubMed ID: 10685628
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer.
Castiglioni T; Merino MJ; Elsner B; Lah TT; Sloane BF; Emmert-Buck MR
Hum Pathol; 1994 Sep; 25(9):857-62. PubMed ID: 8088759
[TBL] [Abstract][Full Text] [Related]
9. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck.
Strojan P; Budihna M; Smid L; Svetic B; Vrhovec I; Kos J; Skrk J
Clin Cancer Res; 2000 Mar; 6(3):1052-62. PubMed ID: 10741734
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of total cathepsin B in invasive ductal carcinoma of the breast.
Budihna M; Skrk J; Zakotnik B; Gabrijelcic D; Lindtner J
Eur J Cancer; 1995; 31A(5):661-4. PubMed ID: 7640035
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin expression in oral squamous cell carcinoma: relationship with clinicopathologic factors.
Kawasaki G; Kato Y; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Apr; 93(4):446-54. PubMed ID: 12029284
[TBL] [Abstract][Full Text] [Related]
13. Cysteine and serine proteases in gastric cancer.
Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R
Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115
[TBL] [Abstract][Full Text] [Related]
14. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
Herszényi L; Farinati F; Cardin R; István G; Molnár LD; Hritz I; De Paoli M; Plebani M; Tulassay Z
BMC Cancer; 2008 Jul; 8():194. PubMed ID: 18616803
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
[TBL] [Abstract][Full Text] [Related]
16. The role of cysteine and serine proteases in colorectal carcinoma.
Herszènyi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
Cancer; 1999 Oct; 86(7):1135-42. PubMed ID: 10506696
[TBL] [Abstract][Full Text] [Related]
17. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
Bussen S; Rempen A; Caffier H
Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
[TBL] [Abstract][Full Text] [Related]
18. Determination of cathepsins B, H, L and kininogen in breast cancer patients.
Gabrijelcic D; Svetic B; Spaić D; Skrk J; Budihna J; Turk V
Agents Actions Suppl; 1992; 38 ( Pt 2)():350-7. PubMed ID: 1334335
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
[TBL] [Abstract][Full Text] [Related]
20. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.
Thorpe SM; Rochefort H; Garcia M; Freiss G; Christensen IJ; Khalaf S; Paolucci F; Pau B; Rasmussen BB; Rose C
Cancer Res; 1989 Nov; 49(21):6008-14. PubMed ID: 2790815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
